described in 1980 by Hansen et al. 1 Due to the rapidly increasing number of HLA-typed volunteers with a present number of more than 3.5 million potential donors world An increasing number of volunteer unrelated donor bone marrow transplantations (VUD-BMT) are perforwide in the donor registries, VUD transplants are performed frequently. However, transplant-related toxicity (TRM) is med every year for hematological malignancies due to the availability of a large donor pool. Here we show the presently high in VUD BMT as compared to matched sibling donor BMT. Predominant problems include results of 36 VUD transplants from our institution using a chemotherapy-only conditioning regimen comprising engraftment failure, acute and chronic graft-versus-host disease (GVHD) and opportunistic infections. Total body busulfan 4 × 4 mg/kg and cyclophosphamide 2 × 60 mg/kg. All patients received heparin 200 IU/kg bw conirradiation (TBI) in combination with cyclophosphamide is regarded to be the most efficient immunosuppressive regitinuous i.v. infusion starting the day before conditioning until day +30. Thirty-four of 36 patients (94%) men for inducing tolerance for engraftment. 2 Disadvantages of radiation-containing regimens include ARDS or longengrafted and no secondary graft failure was observed. The two non-engraftments occurred in patients with term pulmonary dysfunction, cataracts and second malignancies in addition to difficulties due to rigid time sched-CML in blast crisis with extensive myelofibrosis. All 34 engrafted patients (100%) were in complete remission ules of the therapy. Chemotherapy-only regimens have been developed to achieve more flexibility in allogeneic on day +30 as shown by bone marrow biopsy and cytogenetic examinations. No life-threatening treatment-BMT and busulfan has been introduced as a substitute for TBI by Santos and Tutschka. 3,4 Busulfan is an alkylating related morbidity or mortality (TRM) were observed, in particular, no severe veno-occlusive disease (VOD) of agent with high activity against progenitor cells and has excellent penetration into the CNS. 5,6 Presently it is only the liver and no fatal pulmonary complication. Use of G-CSF significantly shortened the time of neutropenia available in tablet form and because of its variation in bioavailability 7 it was thought to have lower immunoby 5 days. GVHD prophylaxis consisted of CsA/methylprednisolone with or without MTX. Acute suppressive activity. 8 However, in combination with cyclophosphamide or VP16 it has been shown to be highly GVHD grade II-IV was observed in 18/34 patients (53%) and cGVHD in 12/27 patients (45%), who suractive in autologous and allogeneic transplantation. 6,[9][10] [11] Randomized and comparative studies have demonstrated vived to day +100. In seven patients (four with HLA class I or II mismatch) anti-T-lymphocyte globulin results as good as those seen with TBI/cyclophosphamide in allogeneic sibling BMT for AML, CML and MDS 4, [12] [13] [14] [15] (ATG) was added for acute GVHD prophylaxis. One of seven had aGVHD grade II and none developed grade except for two randomized trials in patients with good risk hematological disease which showed better results with III to IV GVHD or graft failure. We conclude that Bu/CY is a feasible, save and sufficiently immunosup-TBI. 16, 17 Only few data are available about Bu/CY in VUD-BMT with only small patient numbers. [18] [19] [20] Previously, the pressive regimen for VUD transplantation. Severe acute GVHD might be avoided by additional use of ATG in main toxicity of busulfan involved the liver, and resulted in a high incidence of fatal veno-occlusive disease (VOD) GVHD prophylaxis.
Busulfan/cyclophosphamide in VUD-BMT
H Bertz et al 1170 had an HLA-A micromismatch, four patients had an HLA- CML 16 DR minor mismatch, and in two patients, a DP allele differ-ALL 3 ence existed. MLC was performed in 33 donor/patient pairs MDS/sec AML 7
and was nonreactive in all.
Remission CR1/CP1 13 CR2/CP2 5
Supportive care
AP/BC 5 no remission 13 The patients were housed in a single room with were given according to standard procedures. Where fever persisted after 72 h, microbiological therapy was escalated with amphotericin B; 10 g immunoglobulin was given until day +100 starting day −1 and every 10 days post-transplant.
Table 2
Graft-versus-host disease according to the prophylaxis regimen
Conditioning

Grade
0-I II-IV (%) III-IV (%)
According to Tutschka 4 busulfan 4 mg/kg was administered orally four times a day from days −7 to −4, and cyclophosAcute GVHD in n = 34 phamide 60 mg/kg was given day −3 and −2 i.v. over 1 h. 
GVHD prophylaxis
In four patients GVHD prophylaxis consisted of cyclosporin (CsA) 5 mg/kg twice a day starting day −3, and methyltransplanted between August 1993 and August 1996. The median age was 35.7 years (range 20-50). Blood groups prednisolone (MP) 0.5 mg/kg/day divided in two doses starting day +7 which was increased to 1 mg/kg/day on were identical in 14 donor/recipient pairs. A major ABOmismatch was present in 12, and minor mismatch in 10 day +14 (regimen A). 23 Since January 1994, short course methotrexate (MTX) (day +1 15 mg/ 2 and day +3 and +6 transplants. In 19 transplants, recipient and donor gender 10 mg/m 2 ) 24 was added in 25 patients (regimen B) and the Engraftment dose was adjusted according to direct bilirubin and creatinEngraftment defined as the first of 3 consecutive days with ine levels. CsA blood levels were measured three times a leukocytes Ͼ1000/l was achieved in 34 patients (92%). week and the target level was 300-400 ng/ml blood as mea-
Patients not receiving G-CSF (n = 14) engrafted with a sured by a fluorescence polymerization immunoassay median on day +16.5 (range [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] and patients who (Abbot, Wiesbaden, Germany). All 25 patients received received G-CSF (n = 20) engrafted with a median on day 100% of the target dose of MTX. Since November 1995 +14 (range 12-18). Patients receiving GVHD prophylaxis seven patients received additional anti-T-lymphocyte regimen B and C (n = 10), who did not receive hematoglobulin (ATG; Fresenius, Bad Homburg, Germany) poietic growth factors recovered on a median of day +19.6 (regimen C). ATG 30 mg/kg/day was administered day −3 (range 14-32) and the 20 patients on regimen B and C and until day −1 as a 12-h infusion as GVHD prophylaxis. Four G-CSF recovered on a median of day +14.2 (range 12-18). of these seven patients had micro or minor HLA class I This difference is statistically significant with P Ͻ 0.001 and II mismatches (Tables 1 and 2 ).
( Table 3 ). Two patients transplanted in blast crisis of CML did not engraft. In both cases, pretransplant bone marrow CMV prophylaxis biopsy revealed extensive marrow fibrosis. In one patient a second bone marrow infusion from the same donor without Fifteen recipient and donor pairs were CMV negative. In further conditioning was given, but again no engraftment five transplants, recipient and donor were both positive, in was achieved. The patient died due to invasive aspergillosis five cases only the donor was positive and in 11, only the day +65. The second patient received unselected G-CSF recipient was positive (Table 1) . After engraftment, weekly mobilized PBSC after leukapheresis twice from her hap-CMV-PCR was performed and CMV-antigenemia was loidentical son, but did not engraft and died of pneumonia measured in the blood. CMV prophylaxis was started when on day +122. There is no correlation between nonen-CMV-PCR was positive on two consecutive assays or graftment, transplantation cell count or CFU-GM. Twenty-CMV-antigenemia was detectable. Depending on the platenine of 34 patients who engrafted exceeded a platelet count let count and the blood creatinine, patients received either of 20 000/l with a median on day +29 (range 8-95) withganciclovir 2 × 5 mg/kg/d for 7 days and then once a day, out further transfusion. A median of 96 units (range 15-or foscarnet 2 × 60 mg/kg/day for 14 days and afterwards 246) was transfused to achieve a platelet count above once a day until the PCR was again negative.
10 000/l during aplasia. Five patients died before they were transfusion-independent due to the reasons mentioned Statistical analysis below. Packed red cells were given to keep the hemoglobin above 8.5 g/l, and a median of 12.2 packed red cells (range The median difference was evaluated with the Student's t-0-56) were transfused. test for unpaired data in the two groups without G-CSF.
GVHD
Results
Acute GVHD grade II-IV occurred in 19/34 patients Transplantation (56%), grade II in 12/34 patients (35%) and grade III-IV in seven of 34 patients (21%) and was fatal in five of seven Twenty-two of 36 transplants were performed after separpatients. According to GVHD prophylaxis regimen, we ation by HAES sedimentation because of blood group misobserved aGVHD grade III and IV with regimen A in two matches. The target ANC count for engraftment was of four patients (50%), with regimen B in five of 25 patients 2 × 10 8 /kg and this was reached in 29 patients (82%). The (20%) and with regimen C in none of seven patients (0%). median transplanted nucleated cell count was 2.6 × 10 8 /kg Twenty-seven patients survived to day +100 and chronic (range 1.2-4.2). Bone marrow cultures showed a median GVHD occurred in 12/27 (44%) with a median follow-up growth of 104 CFU-GM/2 × 10 5 cells (range, no growth to of 329 days. Six of 27 patients (22%) suffered from limited 228) after 14 days (Table 3) . disease and six of 27 patients (22%) suffered from extensive disease (Table 2) . All patients (n = 34) who engrafted had histologically proNeutrophils Ͼ1000/l median day +16 (range ven complete remission in the bone marrow biopsy on day The median survival for all patients is 258 days (range duplex sonography. This is most likely due to our heparin prophylaxis regimen which was used in all patients without 32-1263). Sixteen (45%) patients are alive in complete remission with a median follow-up of 455 days (196-1263).
major bleeding complications. Furthermore, no fatal pulmonary complications were observed in contrast to reports Five of 34 (14%) patients relapsed; three patients transplanted with AML in second refractory relapse died on day in the literature with an incidence of up to 21% for busulfan 4,25,26 and 28% for TBI. 29 A longer follow-up is neces-+124, +142 and +164 respectively, one patient with ALL transplanted in second relapse relapsed and died on day sary to estimate the incidence of chronic pulmonary problems including fibrosis. In the future, i.v. preparations of + 512, and one patient with CML transplanted in 2nd AP after one blast crisis on day +241. The latter patient was BU 30 could facilitate its use, with reliable blood levels. Furthermore, tablets with a higher content of busulfan will treated with donor buffy coat cells as adoptive immunotherapy without any response. Two patients died due to chronic make therapy more acceptable for patients. Bu/CY or other busulfan combinations using melphalan, VP16 or cytarab-GVHD on day +205 and day +267 and five patients died of infectious problems: Pneumocystis carinii pneumonia ine 10,28,31 should be randomly compared to TBI-containing regimens in VUD transplants. (PCP) day +341 (1), toxoplasmosis (2) day +380 and +780, pneumonia of unknown origin day +104 (1), and +122 due
We conclude that Bu/CY is a safe and sufficiently immunosuppressive conditioning protocol for HLAto graft failure (1).
During the time on our transplant ward we did not identical and nonidentical VUD transplants. This combination presents a valuable alternative to TBI containing observe any severe pulmonary problems such as interstitial pneumonitis or respiratory failure requiring ventilation supregimens with few side-effects using our prophylaxis protocol. port. No severe VOD was observed and no seizures occurred. Although reactivation of CMV was detectable by PCR and CMV antigenemia, only one organ manifestation of CMV disease was observed as CMV colitis in a patienttwo patients with CML in blast crises with biopsy-proven to that in the literature for patients conditioned with VUD- 
